Bio Path is a biotechnology business based in the US. Bio Path shares (BPTH) are listed on the NASDAQ and all prices are listed in US Dollars. Bio Path employs 10 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.97 |
|---|---|
| 52-week range | $0.92 - $21.60 |
| 50-day moving average | $1.63 |
| 200-day moving average | $5.11 |
| Wall St. target price | $20.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-14.19 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.971 from 2024-09-05
| 1 week (2024-08-30) | -1.58% |
|---|---|
| 1 month (2024-08-06) | -32.10% |
| 3 months (2024-06-06) | -65.07% |
| 6 months (2024-03-06) | -84.92% |
| 1 year (2023-09-06) | 155.53% |
|---|---|
| 2 years (2022-09-06) | -73.03% |
| 3 years (2021-09-03) | 5.56 |
| 5 years (2019-09-06) | 10.98 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -140.03% |
| Return on equity TTM | -366.18% |
| Profit margin | 0% |
| Book value | $0.57 |
| Market Capitalization | $2.5 million |
TTM: trailing 12 months
We're not expecting Bio Path to pay a dividend over the next 12 months.
Bio Path's shares were split on a 1:20 basis on 22 February 2024. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Bio Path shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Bio Path shares which in turn could have impacted Bio Path's share price.
Over the last 12 months, Bio Path's shares have ranged in value from as little as $0.92 up to $21.6. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bio Path's is 0.242. This would suggest that Bio Path's shares are less volatile than average (for this exchange).
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas. .
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.